Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | GALK1 | P51570 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | F10 | P00742 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225715 | 0.82 | F10 (0.76) | MEN1KMT2AMAPTTP53POLB | |
| SCHEMBL5226610 | 0.82 | NR1H4 (0.60) | MEN1KMT2ATP53F10ALDH1A1 | |
| SCHEMBL5225091 | 0.80 | F10 (0.61) | MEN1KMT2AMAPTTP53POLB | |
| SCHEMBL5225151 | 0.80 | F10 (0.61) | MEN1KMT2AMAPTTP53POLB | |
| SCHEMBL5222102 | 0.78 | NR1H4 (0.64) | MAPTGAATP53F10LMNA | |
| SCHEMBL5228240 | 0.76 | NR1H4 (0.62) | MEN1KMT2AMAPTGAAPKM | |
| SCHEMBL5225486 | 0.75 | NR1H4 (0.63) | MEN1KMT2AMAPTTP53POLB | |
| SCHEMBL5223117 | 0.74 | F10 (0.64) | MEN1KMT2AMAPTTP53POLB | |
| SCHEMBL5222813 | 0.74 | NR1H4 (0.60) | MEN1KMT2ATP53ALDH1A1LMNA | |
| SCHEMBL5224050 | 0.73 | NR1H4 (0.60) | MEN1KMT2AMAPTTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1014962-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2007-06-27 | — | — | EP | disclosed |
| US-6605626-B2 | Benzamide inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-08-12 | — | — | US | disclosed |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | BEIGHT DOUGLAS WADE (US) | 2002-08-29 | — | — | US | disclosed |
| US-6313122-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-1014962-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999000121-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | TFPI, F11, F12 | MEN1 1119/4885KMT2A 2083/4885NPSR1 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.